Role of Interleukin-33 in Innate-Type immune cells in allergy

Allergology International

Volumn 62, Issue 1, 2013, Pages 13-20

  Nakae, Susumu ^a,b   Morita, Hideaki ^c   Ohno, Tatsukuni ^d   Arae, Ken ^c,e   Matsumoto, Kenji ^c   Saito, Hirohisa ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e KYORIN UNIVERSITY   (Japan)

Author keywords

Allergy; Basophil; Interleukin 33; Mast cell; Natural helper cell

Indexed keywords

CYTOKINE; INTERLEUKIN 33; INTERLEUKIN 33 RECEPTOR; INTERLEUKIN RECEPTOR; UNCLASSIFIED DRUG;

ALLERGY; BASOPHIL; CELL ADHESION; CELL SURVIVAL; CYTOKINE PRODUCTION; EOSINOPHIL; GENETIC POLYMORPHISM; HELPER CELL; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; INNATE TYPE IMMUNE CELL; LYMPHOID CELL; MAST CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 84875160031     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.13-RAI-0538     Document Type: Review

References (75)

1. Schmitz J, Owyang A, Oldham E et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479-90.
2. Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S. IL-33 and IL-33 receptors in host defense and diseases. Allergol Int 2010;59:143-60.
3. Onda H, Kasuya H, Takakura K et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab 1999;19:1279-88.
4. Baekkevold ES, Roussigne M, Yamanaka T et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 2003;163:69-79.
5. Carriere V, Roussel L, Ortega N et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatinassociated nuclear factor in vivo. Proc Natl Acad Sci U S A 2007;104:282-7.
6. Roussel L, Erard M, Cayrol C, Girard JP. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 2008; 9:1006-12.
7. Werman A, Werman-Venkert R, White R et al. The precursor form of IL-1ffis an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U S A 2004;101: 2434-9.
8. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011;29:139-62.
9. Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci 1998;856:1-11.
10. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27: 519-50.
11. Luthi AU, Cullen SP, McNeela EA et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009;31:84-98.
12. Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem2009;284:19420-6.
13. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 2009;106:9021-6.
14. Ohno T, Oboki K, Kajiwara N et al. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol 2009;183:7890-7.
15. Lefrancais E, Roga S, Gautier V et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A 2012;109:1673-8.
16. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A 2007;104:18660-5.
17. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007;179:2551-5.
18. Palmer G, Lipsky BP, Smithgall MD et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 2008;42:358-64.
19. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-80.
20. Smith DE. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy 2010;40:200-8.
21. Ohno T, Morita H, Arae K, Matsumoto K, Nakae S. Interleukin-33 in allergy. Allergy 2012;67:1203-14.
22. Ho LH, Ohno T, Oboki K et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcbRI signals. J Leukoc Biol 2007;82:1481-90.
23. Iikura M, Suto H, Kajiwara N et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007;87:971-8.
24. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007;179:2051-4.
25. Moritz DR, Rodewald HR, Gheyselinck J, Klemenz R. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J Immunol 1998;161:4866-74.
26. Moulin D, Donze O, Talabot-Ayer D, Mezin F, Palmer G, Gabay C. Interleukin (IL)-33 induces the release of proinflammatory mediators by mast cells. Cytokine 2007;40: 216-25.
27. Kaieda S, Shin K, Nigrovic PA et al. Synovial fibroblasts promote the expression and granule accumulation of tryptase via interleukin-33 and its receptor ST-2 (IL1RL1). J Biol Chem 2010;285:21478-86.
28. Silver MR, Margulis A, Wood N, Goldman SJ, Kasaian M, Chaudhary D. IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm Res 2010;59:207-18.
29. Jung MY, Smrz D, Desai A et al. IL-33 induces a hyporesponsive phenotype in human and mouse mast cells. J Immunol 2013;190:531-8.
30. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1-and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008;20:1019-30.
31. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 2009;113:1526-34.
32. Suzukawa M, Iikura M, Koketsu R et al. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol 2008;181:5981-9.
33. Schneider E, Petit-Bertron AF, Bricard R et al. IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. J Immunol 2009; 183:3591-7.
34. Kroeger KM, Sullivan BM, Locksley RM. IL-18 and IL-33 elicit Th2 cytokines from basophils via a MyD88-and p38p-dependent pathway. J Leukoc Biol 2009;86:769-78.
35. Suzukawa M, Nagase H, Ogahara I et al. Leptin enhances survival and induces migration, degranulation, and cytokine synthesis of human basophils. J Immunol 2011; 186:5254-60.
36. Suzukawa M, Koketsu R, Iikura M et al. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest 2008;88:1245-53.
37. Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 2008;121:1484-90.
38. Chow JY, Wong CK, Cheung PF, Lam CW. Intracellular signaling mechanisms regulating the activation of human eosinophils by the novel Th2 cytokine IL-33: implications for allergic inflammation. Cell Mol Immunol 2010;7:26-34.
39. Wakahara K, Baba N, Van VQ et al. Human basophils interact with memory T cells to augment Th17 responses. Blood 2012;120:4761-71.
40. Moro K, Yamada T, Tanabe M et al. Innate production of TH2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cells. Nature 2010;463:540-4.
41. Neill DR, Wong SH, Bellosi A et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010;464:1367-70.
42. Saenz SA, Siracusa MC, Perrigoue JG et al. IL25 elicits a multipotent progenitor cell population that promotes TH2 cytokine responses. Nature 2010;464:1362-6.
43. Price AE, Liang HE, Sullivan BM et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A 2010;107:11489-94.
44. Koyasu S, Moro K. Type 2 innate immune responses and the natural helper cell. Immunology 2011;132:475-81.
45. Saenz SA, Noti M, Artis D. Innate immune cell populations function as initiators and effectors in Th2 cytokine responses. Trends Immunol 2010;31:407-13.
46. Barlow JL, McKenzie AN. Nuocytes: expanding the innate cell repertoire in type-2 immunity. J Leukoc Biol 2011;90:867-74.
47. Hoyler T, Klose CS, Souabni A et al. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity 2012;37:634-48.
48. Koyasu S, Moro K. Innate Th2-type immune responses and the natural helper cell, a newly identified lymphocyte population. Curr Opin Allergy Clin Immunol 2011;11:109-14.
49. Liang HE, Reinhardt RL, Bando JK, Sullivan BM, Ho IC, Locksley RM. Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity. Nat Immunol 2011;13:58-66.
50. Wilhelm C, Hirota K, Stieglitz B et al. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol 2011;12:1071-7.
51. Barlow JL, Bellosi A, Hardman CS et al. Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. J Allergy Clin Immunol 2012;129:191-8. e1-4.
52. Brickshawana A, Shapiro VS, Kita H, Pease LR. Lineage-Sca1+c-Kit-CD25+ cells are IL-33-responsive type 2 innate cells in the mouse bone marrow. J Immunol 2011;187: 5795-804.
53. Monticelli LA, Sonnenberg GF, Abt MC et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 2011;12:1045-54.
54. Ikutani M, Yanagibashi T, Ogasawara M et al. Identifica tion of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J Immunol 2012;188:703-13.
55. Bartemes KR, Iijima K, Kobayashi T, Kephart GM, McKenzie AN, Kita H. IL-33-responsive lineage-CD25+ CD44hi lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol 2012; 188:1503-13.
56. Gudbjartsson DF, Bjornsdottir US, Halapi E et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet 2009; 41:342-7.
57. Oshikawa K, Kuroiwa K, Tago K et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001;164: 277-81.
58. Ali M, Zhang G, Thomas WR et al. Investigations into the role of ST2 in acute asthma in children. Tissue Antigens 2009;73:206-12.
59. Prefontaine D, Lajoie-Kadoch S, Foley S et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009;183: 5094-103.
60. Prefontaine D, Nadigel J, Chouiali F et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 2010;125:752-4.
61. Kondo Y, Yoshimoto T, Yasuda K et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008;20:791-800.
62. Nishikado H, Mukai K, Kawano Y, Minegishi Y, Karasuyama H. NK cell-depleting anti-asialo GM1 antibody exhibits a lethal off-target effect on basophils in vivo. J Immunol 2011;186:5766-71.
63. Chua KY, Stewart GA, Thomas WR et al. Sequence analysis of cDNA coding for a major house dust mite allergen, Der p 1. Homology with cysteine proteases. J Exp Med 1988;167:175-82.
64. Oboki K, Ohno T, Kajiwara N et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A 2010;107:18581-6.
65. Milne J, Brand S. Occupational asthma after inhalation of dust of the proteolytic enzyme, papain. Br J Ind Med 1975; 32:302-7.
66. Halim TY, Krauss RH, Sun AC, Takei F. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 2012;36:451-63.
67. Shimizu M, Matsuda A, Yanagisawa K et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum Mol Genet 2005;14:2919-27.
68. Matsuda A, Okayama Y, Terai N et al. The role of interleukin-33 in chronic allergic conjunctivitis. Invest Ophthalmol Vis Sci 2009;50:4646-52.
69. Hueber AJ, Alves-Filho JC, Asquith DL et al. IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol 2011;41:2229-37.
70. Sakashita M, Yoshimoto T, Hirota T et al. Association of serum interleukin-33 level and the interleukin-33 genetic variant with Japanese cedar pollinosis. Clin Exp Allergy 2008;38:1875-81.
71. Castano R, Bosse Y, Endam LM, Desrosiers M. Evidence of association of interleukin-1 receptor-like 1 gene polymorphisms with chronic rhinosinusitis. Am J Rhinol Allergy 2009;23:377-84.
72. Asaka D, Yoshikawa M, Nakayama T, Yoshimura T, Moriyama H, Otori N. Elevated levels of interleukin-33 in the nasal secretions of patients with allergic rhinitis. Int Arch Allergy Immunol 2012;158 (Suppl 1):47-50.
73. Haenuki Y, Matsushita K, Futatsugi-Yumikura S et al. A critical role of IL-33 in experimental allergic rhinitis. J Allergy Clin Immunol 2012;130:184-94. e11.
74. Kim YH, Yang TY, Park CS et al. Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy 2012;67:183-90.
75. Mjosberg JM, Trifari S, Crellin NK et al. Human IL-25-and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011;12:1055-62.